Loading
A phase 2 trial of Fostamatinib and Ruxolitinib in Primary myelofibrosis, run by Washington University School of Medicine, recorded as terminated on the registry.
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia is a phase 2 interventional study registered as NCT04543279 by Washington University School of Medicine, with 3 participants recorded, started 2021-05-03 and due to reach its primary completion in 2022-07-01. Interventions recorded: Fostamatinib, Ruxolitinib. Conditions recorded: Myelofibrosis, Thrombocytopenia.
Linked to the drug Fostamatinib because the registry names it among its interventions and Primary myelofibrosis among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
3 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2023-12-15), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With a Platelet Response (Part A)primary | Part A: Fostamatinib | 3 | 0 participants | - | - | link |
Shares Fostamatinib and the tag pipeline.
Shares Fostamatinib and the tag pipeline.
Shares Ruxolitinib, Primary myelofibrosis and the tag pipeline.
Shares Ruxolitinib, Primary myelofibrosis and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.
Shares Ruxolitinib and the tag pipeline.
Shares Ruxolitinib and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.